Psychotropic drug–related weight gain (PDWG) is a common occurrence and is highly
associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs …

Schizophrenia is a chronic neuropsychiatric syndrome that significantly impacts daily
function and quality of life. All of the available guidelines suggest a combined treatment …

Bipolar depression remains a clinical challenge with a quarter of patients failing to respond
to initial conventional treatments. Although ketamine has been extensively studied in …

This study aimed to evaluate the efficacy and safety of lumateperone in treating bipolar
disorder and schizophrenia. A comprehensive literature search was conducted across …

Background Lumateperone has been approved by the Food and Drug Administration (FDA)
for the treatment of schizophrenia in adults since 2019, however, there is still a lack of data …

Objective Lumateperone, a novel antipsychotic drug that was granted by the Food and Drug
Administration (FDA) approval in December 2019, remains insufficiently explored for its …

Schizophrenia is a chronic psychotic disorder comprising positive symptoms, negative
symptoms, and cognitive deficits. Negative symptoms are associated with stigma, worse …

Lumateperone (Caplyta, Intra-Cellular Therapies) is a new antipsychotic medication,
approved by the Food and Drug Administration (FDA) in 2019 for adults with schizophrenia …

Schizophrenia is a devastating chronic mental health illness which includes a complex set of
symptoms like hallucination, illusion and delusion, and to manage, lifelong antipsychotic …

Ketamine is an N-methyl-d-aspartate receptor antagonist that is emerging as an effective,
rapid-acting antidepressant for patients with treatment-resistant depression (1–3). Ketamine …